• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0
×

Target

Host

Species Reactivity

Species Reactivity

Conjugate

Conjugate

  • HEK293 expressed
  • Endotoxin-free
  • Animal-component free

HumanKine® recombinant human GM-CSF protein

Activity

0.08-0.8 ng/mL

Specific Activity

minimally 6.00x106 IU/mg

Species Reactivity

human,mouse,pig

Purity

>95%

Publications(32)

Cat no : HZ-1002

Synonyms

Colony stimulating factor, CSF, CSF2, GM CSF, GMCSF, GM-CSF, Molgramostin, Sargramostim

Validation Data Gallery

  • Purity of recombinant human GM-CSF was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue.

    Purity of recombinant human GM-CSF was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue.

  • The activity was determined by dose-dependent stimulation of proliferation in human TF-1 cells (human erythroleukemic indicator cell line) measured using Promega CellTiter96® Aqueous Non-Radioactive Cell Proliferation Assay.

    The activity was determined by dose-dependent stimulation of proliferation in human TF-1 cells (human erythroleukemic indicator cell line) measured using Promega CellTiter96® Aqueous Non-Radioactive Cell Proliferation Assay.

Technical Specifications

GeneID 1437
Species Human
Expression HEK293
Activity 0.08-0.8 ng/mL
Specific Activityminimally 6.00x106 IU/mg
Purity >95%
Endotoxin<1 EU/µg
Accession NumberP04141
Molecular Mass 15 to 36 kDa reduced and non-reduced, monomer, glycosylated
Formulation 1x PBS, See Certificate of Analysis for details
Species Reactivity human,mouse,pig

Stability and Reconstitution

Stability and StorageProduct FormTemperature ConditionsStorage Time
(From Date of Receipt)
Lyophilized-20°C to -80°CUntil Expiry Date
LyophilizedRoom Temperature2 weeks
Reconstituted as per CofA-20°C to -80°C6 months
Reconstituted as per CofA4°C1 week
Avoid repeated freeze-thaw cycles.
Reconstitution Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein to 0.2 mg/mL in sterile 1xPBS pH 7.4 containing 0.1% endotoxin-free recombinant human serum albumin (HSA). Gently swirl or tap vial to mix.

Background

Granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as colony-stimulating factor 2 (CSF2), is a monomeric glycoprotein secreted by macrophages, T cells, mast cells, natural killer cells, endothelial cells and fibroblasts. GM-CSF is a hematopoietic growth factor that stimulates the development of early erythroid megakaryocytic and eosinophilic progenitor cells (PMID 2990035). GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes (PMID 3021817, 2984574, 6390681).

Synonyms

Colony stimulating factor, CSF, CSF2, GM CSF, GMCSF, GM-CSF, Molgramostin, Sargramostim

Publications

SpeciesTitle

ACS Nano

Engineered Norovirus-Derived Nanoparticles as a Plug-and-Play Cancer Vaccine Platform

Authors - Peng Zheng
View Article
human

Blood

GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.

Authors - EricPadron
View Article
mouse

Small Methods

Pre-Induced ICD Membrane-Coated Carrier-Free Nanoparticles for the Personalized Lung Cancer Immunotherapy

Authors - Shilin Li
View Article
human

J Exp Med

Inherited TNFSF9 deficiency causes broad Epstein-Barr virus infection with EBV+ smooth muscle tumors.

Authors - Benjamin Fournier
View Article
mouse

ACS Appl Mater Interfaces

Combined Chemo-Immuno-Photothermal Therapy for Effective Cancer Treatment via an All-in-One and One-for-All Nanoplatform

Authors - Xianglong Yu
View Article

Biomaterials

In situ repurposing of dendritic cells with CRISPR/Cas9-based nanomedicine to induce transplant tolerance.

Authors - Yue Zhang
View Article